Diabetes Engagement and Activation Platform



Status:Completed
Conditions:Diabetes
Therapuetic Areas:Endocrinology
Healthy:No
Age Range:18 - 75
Updated:11/11/2018
Start Date:November 1, 2017
End Date:November 5, 2018

Use our guide to learn which trials are right for you!

DEAP: Diabetes Engagement and Activation Platform

The following are hypothesized:

1. The Diabetes Engagement and Activation Platform (DEAP) can be integrated into primary
care workflow to facilitate the care of patients with type 2 diabetes.

2. The DEAP intervention will be feasible and acceptable to patients with type 2 diabetes.

3. The DEAP intervention will enhance patient activation and improve type 2 diabetes self
management and glucose control

Aim 1: To evaluate how primary care practices adopt and integrate DEAP into routine workflow
including identification of barriers and facilitators to support acceptable, feasible, and
sustainable use of the system.

- Sub-aim 1.1: Measure the proportion of clinicians and care team members who engage
patients through the DEAP intervention as well as the types of patient support
activities they address; assess the representativeness of participating clinicians and
care team members in relation to all practice staff; and assess how they integrated DEAP
into the care of type 2 diabetes patients.

- Sub-aim 1.2: Assess how practices redesign workflow, overcome barriers, and enhance
facilitators in order to integrate DEAP.

- Sub-aim 1.3: Determine processes for sustaining DEAP beyond the project funding period .

Aim 2: To compare, relative to usual care, the effectiveness of the DEAP intervention.

- Sub Aim 2.1: Measure the proportion and representativeness of eligible patients who
choose to enroll; access the DEAP curriculum; complete the DEAP curriculum; and contact
care team members. .

- Sub Aim 2.2: Compare the change in the average glycosylated hemoglobin (primary
outcome), Body Mass Index, systolic blood pressure, and type 2 diabetes (T2D)
medications and patient activation (secondary outcomes) from baseline to 3 months and
from 3 to 6 months for patients randomized to DEAP versus usual care.

Sub Aim 2.3: Assess the clarity, readability and acceptability of the DEAP curricula
materials for T2D patients enrolled in the intervention.

Inclusion Criteria:

- Patients diagnosed with type 2 diabetes and A1C measure ≥ 8%;

- English speaking;

- Enrolled in the practice EHR linked patient portal.

Exclusion Criteria:

- Patients without type 2 diabetes or with type 2 diabetes who have a A1C less than or
equal to 7.9%;

- Non-English speaking;

- Patients not enrolled in the practice EHR linked patient portal;

- Under 18 and over 75 years of age.
We found this trial at
1
site
Richmond, Virginia 23298
(804) 828-0100
Virginia Commonwealth University Since our founding as a medical school in 1838, Virginia Commonwealth University...
?
mi
from
Richmond, VA
Click here to add this to my saved trials